A carregar...
The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia
Idelalisib is a first in class, delta isoform specific, PI3-kinase inhibitor. Based on its high level of efficacy and acceptable safety profile, this oral drug has been approved by the US Food and Drug Administration as a single agent for the treatment of relapsed or refractory small lymphocytic lym...
Na minha lista:
| Publicado no: | Ther Adv Hematol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4802506/ https://ncbi.nlm.nih.gov/pubmed/27054023 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620715625966 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|